Sequent Scientific Limited (NSE:SEQUENT) Q2 FY23 Earnings Concall dated Nov. 08, 2022 Corporate Participants: Abhishek Singhal -- Head of Investor Relations Rajaram
Categories
Health Care
Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings ConCall Transcript
Dr Lal PathLabs Ltd (NSE:LALPATHLAB) Q2 FY23 Earnings Concall dated Nov. 08, 2022 Corporate participants: Arvind Lal -- Executive Chairman Om Prakash
Metropolis Healthcare Limited (METROPOLIS) Q2 FY23 Earnings Concall Transcript
Metropolis Healthcare Limited (NSE:METROPOLIS) Q2 FY23 Earnings Concall dated Nov. 08, 2022 Corporate Participants: Ameera Shah -- Managing Director Rakesh Agarwal --
Divi’s Laboratories Ltd Q2 FY23 Earnings Conference Call Insights
https://youtu.be/e1-tljnhSVM Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q2 FY23 Earnings Concall Management Update: [00:06:48] DIVISLAB stated that though global logistics scenario
Divi’s Laboratories Q2FY23; 19% Fall in Profits
Divi's Laboratories Ltd.'s revenues in Q2FY23 fell 7% to ₹ 1,855 crores. Consolidated Profit came at ₹ 494 crores showcasing a 19%
Rossari Biotech Ltd (ROSSARI) Q2 FY23 Earnings Concall Transcript
Rossari Biotech Ltd (NSE:ROSSARI) Q2 FY23 Earnings Concall dated Nov. 07, 2022 Corporate Participants: Anoop Poojari -- Client Manager Edward Menezes --
Tarsons Products Limited (TARSONS) Q2 FY23 Earnings Concall Transcript
Tarsons Products Limited (NSE:TARSONS) Q2 FY23 Earnings Concall dated Nov. 07, 2022 Corporate Participants: Rohan Sehgal -- Whole Time Director Santosh Agarwal --
Cipla Limited (CIPLA) Q2 FY23 Earnings Concall Transcript
Cipla Limited (NSE: CIPLA) Q2 FY23 Earnings Concall dated Nov. 04, 2022 Corporate Participants: Naveen Bansal -- Head of Investor Relations Ashish Adukia -- Global Chief
Hester Biosciences Limited (HESTERBIO) Q2 FY23 Earnings Concall Transcript
Hester Biosciences Limited (NSE:HESTERBIO) Q2 FY23 Earnings Concall dated Nov. 04, 2022 Corporate Participants: Rajiv Gandhi -- Chief Executive Officer and Managing Director
Sun Pharmaceutical Industries Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from Sun Pharmaceutical Industries Limited (SUNPHARMA) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:46] Tushar Manudhane of Motilal Oswal asked about
Max Healthcare Institute Ltd (MAXHEALTH) Q2 FY23 Earnings Concall Transcript
Max Healthcare Institute Ltd (NSE:MAXHEALTH) Q2 FY23 Earnings Concall dated Nov. 02, 2022 Corporate Participants: Suraj Digawalekar -- CDR India Investor Relations
Sun Pharmaceutical Industries Limited (SUNPHARMA) Q2 FY23 Earnings Concall Transcript
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Q2 FY23 Earnings Concall dated Nov. 01, 2022 Corporate Participants: Nimish Desai -- Investor Relations Dilip S.
Glenmark Life Sciences Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/FHgUfHa30gw Key highlights from Glenmark Life Sciences Limited (GLS) Q2 FY23 Earnings Concall Management Update: [00:02:53] GLS said that the demand softness
Laurus Labs Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/ZaM0EH45MvA Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Management Update: [00:10:45] LAURUSLABS said that on the R&D front,
Gland Pharma Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/4X77Cs34eLo Key highlights from Gland Pharma Limited (GLAND) Q2 FY23 Earnings Concall Management Update: [00:02:23] GLAND said it saw improvement in supplies
Gland Pharma Limited (GLAND) Q2 FY23 Earnings Concall Transcript
Gland Pharma Limited (NSE:GLAND) Q2 FY23 Earnings Concall dated Oct. 26, 2022 Corporate Participants: Sumanta Bajpayee — Vice President, Corporate Finance and Investor Relations
Torrent Pharmaceuticals Ltd Q2 FY23 Earnings Conference Call Insights
Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q2 FY23 Earnings Concall Q&A Highlights: [00:06:41]Damayanti Kerai from HSBC asked about split of India
Jubilant Pharmova reports dip in its net profit by 97% for Q2FY23
Jubilant Pharmova reported total income of INR 1,599.5 crores during the period ended September 30, 2022 as compared to INR 1,657.7 crores
Torrent Pharmaceuticals Limited Q2FY23; Profits down by 1%
Torrent Pharmaceuticals Ltd.‘s Revenues for Q2 FY23 has increased by 7% YoY to ₹ 2,291 crores. Net Profit fell by 1% YoY
Torrent Pharmaceuticals Ltd (TORNTPHARM) Q2 FY23 Earnings Concall Transcript
Torrent Pharmaceuticals Ltd (NSE:TORNTPHARM) Q2 FY23 Earnings Concall dated Oct. 21, 2022 Corporate Participants: Sudhir Menon -- Chief Financial Officer & Executive
SBI LIFE INSURANCE CO LTD (SBILIFE) Q2 FY23 Earnings Concall Transcript
SBI LIFE INSURANCE CO LTD (NSE:SBILIFE) Q2 FY23 Earnings Concall dated Oct. 21, 2022 Corporate Participants: Mahesh Kumar Sharma -- Managing Director